Palmer CN, Hsu MH, Griffin HJ, Johnson EF. Novel sequence determinants in peroxisome proliferator signaling. J Biol Chem. 1995;270(27):16114–21.
Article CAS PubMed Google Scholar
Zhang Z, Xu Y, Xu Q, Hou Y. PPARgamma against tumors by different signaling pathways. Onkologie. 2013;36(10):598–601.
Gou Q, et al. PPARgamma inhibited tumor immune escape by inducing PD-L1 autophagic degradation. Cancer Sci. 2023;114(7):2871–81.
Article CAS PubMed PubMed Central Google Scholar
Xu L, et al. PPARgamma agonist inhibits c-Myc-mediated colorectal cancer tumor immune escape. J Cell Biochem. 2023;124(8):1145–54.
Article CAS PubMed Google Scholar
Xu Y, et al. SULT1E1 inhibits cell proliferation and invasion by activating PPARgamma in breast cancer. J Cancer. 2018;9(6):1078–87.
Article PubMed PubMed Central Google Scholar
Wang Y, et al. VSP-17, a New PPARgamma Agonist, Suppresses the Metastasis of Triple-Negative Breast Cancer via Upregulating the Expression of E-Cadherin. Molecules. 2018. https://doi.org/10.3390/molecules23010121.
Article PubMed PubMed Central Google Scholar
Cao LQ, et al. Activation of peroxisome proliferator-activated receptor-gamma (PPARgamma) inhibits hepatoma cell growth via downregulation of SEPT2 expression. Cancer Lett. 2015;359(1):127–35.
Article CAS PubMed Google Scholar
To KKW, Wu WKK, Loong HHF. PPARgamma agonists sensitize PTEN-deficient resistant lung cancer cells to EGFR tyrosine kinase inhibitors by inducing autophagy. Eur J Pharmacol. 2018;823:19–26.
Article CAS PubMed Google Scholar
Mehus AA, et al. Activation of PPARgamma and inhibition of cell proliferation reduces key proteins associated with the basal subtype of bladder cancer in As3+-transformed UROtsa cells. PLoS ONE. 2020;15(8): e0237976.
Article CAS PubMed PubMed Central Google Scholar
Tashiro Y, et al. Ischemia reperfusion-induced metastasis is resistant to PPARgamma agonist pioglitazone in a murine model of colon cancer. Sci Rep. 2020;10(1):18565.
Article CAS PubMed PubMed Central Google Scholar
Hernandez-Quiles M, et al. TRIB3 Modulates PPARgamma-Mediated Growth Inhibition by Interfering with the MLL Complex in Breast Cancer Cells. Int J Mol Sci. 2022. https://doi.org/10.3390/ijms231810535.
Article PubMed PubMed Central Google Scholar
Hua TNM, et al. PPARgamma-mediated ALDH1A3 suppression exerts anti-proliferative effects in lung cancer by inducing lipid peroxidation. J Recept Signal Transduct Res. 2018;38(3):191–7.
Article CAS PubMed Google Scholar
Chang HK, et al. Inhibition of ERK activity enhances the cytotoxic effect of peroxisome proliferator-activated receptor gamma (PPARgamma) agonists in HeLa cells. Biochem Biophys Res Commun. 2017;482(4):843–8.
Article CAS PubMed Google Scholar
Pu Z, Zhu M, Kong F. Telmisartan prevents proliferation and promotes apoptosis of human ovarian cancer cells through upregulating PPARgamma and downregulating MMP-9 expression. Mol Med Rep. 2016;13(1):555–9.
Article CAS PubMed Google Scholar
Xu YY, et al. PPARgamma inhibits breast cancer progression by upregulating PTPRF expression. Eur Rev Med Pharmacol Sci. 2019;23(22):9965–77.
Yamashita H, et al. Repression of transcription factor AP-2 alpha by PPARgamma reveals a novel transcriptional circuit in basal-squamous bladder cancer. Oncogenesis. 2019;8(12):69.
Article CAS PubMed PubMed Central Google Scholar
Hou Y, Moreau F, Chadee K. PPARgamma is an E3 ligase that induces the degradation of NFkappaB/p65. Nat Commun. 2012;3:1300.
Hou Y, et al. PPARgamma E3 ubiquitin ligase regulates MUC1-C oncoprotein stability. Oncogene. 2014;33(49):5619–25.
Article CAS PubMed Google Scholar
Fujita M, et al. Cytotoxicity of 15-deoxy-Delta(12,14)-prostaglandin J(2) through PPARgamma-independent pathway and the involvement of the JNK and Akt pathway in renal cell carcinoma. Int J Med Sci. 2012;9(7):555–66.
Article CAS PubMed PubMed Central Google Scholar
Liu J, et al. Bergenin inhibits bladder cancer progression via activating the PPARgamma/PTEN/Akt signal pathway. Drug Dev Res. 2021;82(2):278–86.
Article CAS PubMed Google Scholar
Ai X, et al. Bexarotene inhibits the viability of non-small cell lung cancer cells via slc10a2/PPARgamma/PTEN/mTOR signaling pathway. BMC Cancer. 2018;18(1):407.
Article PubMed PubMed Central Google Scholar
Han M, et al. Hispidulin inhibits hepatocellular carcinoma growth and metastasis through AMPK and ERK signaling mediated activation of PPARgamma. Biomed Pharmacother. 2018;103:272–83.
Article CAS PubMed Google Scholar
Zou Y, et al. Polyunsaturated Fatty Acids from Astrocytes Activate PPARgamma Signaling in Cancer Cells to Promote Brain Metastasis. Cancer Discov. 2019;9(12):1720–35.
Article CAS PubMed PubMed Central Google Scholar
Rinaldi L, et al. Loss of Dnmt3a and Dnmt3b does not affect epidermal homeostasis but promotes squamous transformation through PPAR-gamma. Elife. 2017. https://doi.org/10.7554/eLife.21697.
Article PubMed PubMed Central Google Scholar
Musicant AM, et al. CRTC1/MAML2 directs a PGC-1alpha-IGF-1 circuit that confers vulnerability to PPARgamma inhibition. Cell Rep. 2021;34(8): 108768.
Article CAS PubMed PubMed Central Google Scholar
Cheng S, et al. PPARgamma inhibition regulates the cell cycle, proliferation and motility of bladder cancer cells. J Cell Mol Med. 2019;23(5):3724–36.
Article CAS PubMed PubMed Central Google Scholar
Sippel TR, et al. Activation of PPARgamma in Myeloid Cells Promotes Progression of Epithelial Lung Tumors through TGFbeta1. Mol Cancer Res. 2019;17(8):1748–58.
Article CAS PubMed PubMed Central Google Scholar
Khandekar MJ, et al. Noncanonical agonist PPARgamma ligands modulate the response to DNA damage and sensitize cancer cells to cytotoxic chemotherapy. Proc Natl Acad Sci U S A. 2018;115(3):561–6.
Article CAS PubMed PubMed Central Google Scholar
Liu RZ, et al. The FABP12/PPARgamma pathway promotes metastatic transformation by inducing epithelial-to-mesenchymal transition and lipid-derived energy production in prostate cancer cells. Mol Oncol. 2020;14(12):3100–20.
Article CAS PubMed PubMed Central Google Scholar
Wang J, et al. A novel multifunctional mitochondrion-targeting NIR fluorophore probe inhibits tumour proliferation and metastasis through the PPARgamma/ROS/beta-catenin pathway. Eur J Med Chem. 2023;258: 115435.
Article CAS PubMed Google Scholar
Forootan FS, et al. Fatty acid activated PPARgamma promotes tumorigenicity of prostate cancer cells by up regulating VEGF via PPAR responsive elements of the promoter. Oncotarget. 2016;7(8):9322–39.
Article PubMed PubMed Central Google Scholar
Wu B, et al. PPARgamma inhibition boosts efficacy of PD-L1 Checkpoint Blockade Immunotherapy against Murine Melanoma in a sexually dimorphic manner. Int J Biol Sci. 2020;16(9):1526–35.
Article CAS PubMed PubMed Central Google Scholar
Wu B, et al. Adipose PD-L1 Modulates PD-1/PD-L1 Checkpoint Blockade Immunotherapy Efficacy in Breast Cancer. Oncoimmunology. 2018;7(11): e1500107.
Article PubMed PubMed Central Google Scholar
Xiong Z, et al. Targeting PPAR-gamma counteracts tumour adaptation to immune-checkpoint blockade in hepatocellular carcinoma. Gut. 2023;72(9):1758–73.
Article CAS PubMed Google Scholar
Erra Diaz F, et al. Concomitant inhibition of PPARgamma and mTORC1 induces the differentiation of human monocytes into highly immunogenic dendritic cells. Cell Rep. 2023;42(3): 112156.
Article CAS PubMed Google Scholar
Prat M, et al. PPARgamma activation modulates the balance of peritoneal macrophage populations to suppress ovarian tumor growth and tumor-induced immunosuppression. J Immunother Cancer. 2023. https://doi.org/10.1136/jitc-2023-007031.
留言 (0)